Mercados españoles cerrados en 5 hrs 19 min

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
150,26-0,92 (-0,61%)
Al cierre: 4:00PM EDT
Inicia sesión para publicar un mensaje.
  • s
    stocktargetadvisor
    $JAZZ conversation
    $JAZZ
    Target Raised by HC Wainwright Buy USD 175 » USD 185
  • v
    voodoovaj
    $VXRT conversation
    I think people are under valuing the appointment of Karen J Wilson. Check out the performance of $JAZZ. This lady knows what she is doing. Likely big money incoming.
  • a
    alex
    That’s the tweet from a guy called the tamiflu fighters

    Akash at Wolfe (razor sharp btw) one of first on sellside to come out talking about $JAZZ once-nightly and low sodium oxybate (the $AVDL killer)

    Notes PK profile appears roughly in line with AVDL and quick route to market (PK studies straight to Ph3)

    Bullish
  • M
    Michael
    I think people are over valuing the appointment of Karen J Wilson. Check out the performance of $JAZZ. The lady doesn’t know what she is doing. Likely big loss incoming.
  • J
    Jack
    $AVDL conversation
    JD on Twitter:

    Think it’s bullish for $AVDL for expectations of raise after Ft-218 data to pressure $JAZZ into buyout.
  • O
    Olivier
    $AVDL conversation
    From investor village... Can you confirm that axs12 is no competition for us... Marrhew. Oblo??? It is only a stimulant... I want to be sure.... Hope the author is Wright about umd4... Please confirm your expressions oblio.... Jazz 10k
    If AXSM AXS-12 is successful with data in the 2Q, FT-218 is close to worthless (program would probably be sold to $JAZZ for low price). However, there would be hope with UMD 4, only because/if the safety improvements are sufficient for regular patent life of a new drug or NCE 5-yr regulatory exclusivity + 6-month pediatric extension. This would be huge because it would be re-priced up many times to be in the $100-200m annual sales range ad 90% GM and no marketing spend & no Eclat 20% royalties. I'll be back to this board after AXSM AXS-12 readout in 2Q. From this price level, it would be a reasonable bet on UMD alone. I'm not involved in AVDL but may consider now that ceo is gone after we see the AXSM data. The only other event that might help is if they present pk curves at SLEEP2019, which the dummy ceo would never do, even though I and many had urged him to do it.

    e-mail to a friend printer-friendly
  • b
    bob weottababyitsaboy
    From $JAZZ and $TXMD approvals this weekend we learned that Saturday approvals are released late aftermarket Friday afternoon and Sunday approvals are released premarket Monday morning.
  • J
    Jeff
    $AVDL conversation
    JD Alexander

    @Jdalexander64
    ·
    3h

    Tweet from J.D. Alexander

    First time $AVDL didn't take Q&A for what was otherwise a good quarter & newly empowered management could have taken victory lap with FT-218 wrapping up. Wonder if $AVDL is in BD discussions with $JAZZ for FT-218?
  • r
    ridingbreakouts
    $AVEO conversation
    What did $AVEO file with the SEC on March 18, 2019? A CT Form. Why? Know one knows. If I was short, I would be very nervous. Pre-market, After-market any day a big green triple digit could occur. $AZN $BMY $JAZZ $PFE $CELG
    https://www.investopedia.com/terms/c/confidential-treatment-order.asp
    A confidential treatment order provides confidential treatment for certain documents and information that a company would otherwise have to file.
    A confidential treatment order provides confidential treatment for certain documents and information that a company would otherwise have to file.
    www.investopedia.com
  • S
    SniperTarget_stocks
    $AMRN conversation
    I always love buying pharmaceutical companies under $20. With the rising population and increase in demand. Bought the $JAZZ back in 2012 under $20. Let’s go $AMRN team! People are lonely in today’s world stuck to their iPhones and causes increased health issues
  • M
    Mathew
    $AVDL conversation
    Ok here is JD Alex”s tweet: “Wouldn't be surprised to see the 7.5g AUC once-nightly $AVDL FT-218 being equivalent to $JAZZ Xyrem 9g dose, the most efficacious Xyrem dose but also the dose with the most SAEs. I expect FT-218 will have a once-nightly 7.5g FT-218 dose as the highest. Goodbye XYREM!”

    There you go!!! I hope his assessment comes true!! GLTALs!!
  • A
    AIKIDO
    $AVDL late stage Narcolepsy is more superior than $AXSM and $JAZZ , SP should triple
  • r
    ridingbreakouts
    $AVEO conversation
    $AZN has over $6 Billion cash. AZN free cash flow per quarter is over $350 million plus.
    Maybe AZN really wants IMFINZI to have a deep future with AVEO/s Fotivda Tivozanib.
    $BMY Bristol Myers 5 year chart looks brutal.
    Let us go bidding war: $JAZZ $BMY $AZN $PFE
  • r
    ridingbreakouts
    $AVEO conversation
    My TAKE is National Securities has 30+ people on this board in attempt to drive down PPS. Hope they EVISCERATED and cover 50% higher then 100% higher then 500%++ higher. EUSA mgmt. all JAZZ Pharma past execs. JAZZ pharma went from 75 cents to 170 or UP 17,000%. LONG and STRONG $AVEO $JAZZ
  • R
    Robin
    Axsome Therapeutics, Inc.
    Takeda's TAK-925 shows encouraging action in early-stage narcolepsy study https://seekingalpha.com/news/3501963?source=ansh $TAK, $TAK, $JAZZ
  • r
    ridingbreakouts
    $AVEO conversation
    Pump and dump? Sure. With its pipeline deep with Bristol Myers and AstraZeneca, CanBridge, Biodesix. Kidney cancer drug approved in 30 countries 1st RCC oncology via EU, NICE, ESMO. $AZN $BMY $JAZZ $AVEO
    Cash through 1st QRTR excluding NEW cash milestones which should be pouring in soon
  • A
    AIKIDO
    AVDL could triple pretty quickly $AXSM $JAZZ $JNJ $BHVN , very bullish
  • N
    Nick
    $JAZZ conversation
    As i sit here and analyze this massive move higher today on 1/18/2017 I have to ask how is this fraudulent company worth 10 billion dollars. Their compound that they bought for osa/narcolepsy is a amino acid derivative. Def not a blockbuster drug erwinase is absolute junk xyrem is junk and lost its patent and difetelio another compound that was bought is also not a blockbuster drug. So what fraud entity is pushing this thing higher and higher. 10 billion dollars for a company that is imploding
  • d
    david
    $JAZZ conversation
    Thanks Hillary ! You need to think of the economic consequences to the market and all the little people who own some shares in their retirement. Think before you say stupid things about the markets.
  • b
    bob weottababyitsaboy
    $JAZZ and $TXMD both have PDUFA’s scheduled for this weekend; 10/27 and 10/28 respectfully. As far as I can tell neither has announced anything post market about their approval. That leads me to believe that we won’t hear until 11/5. Stay Long and don’t sell.